Statin deprescribing 'ups event rates' in elderly
A population-based study in patients with polypharmacy shows an increased risk of death
Discontinuing a statin in over-65s poses a significant risk for fatal and nonfatal cardiovascular events, Italian researchers say.
“Polypharmacy is a major health concern among older adults. While deprescribing may reduce inappropriate medicine use, its effect on clinical end points remains uncertain," write Dr Annalisa Biffi of the University of Milano-Bicocca and colleagues.
The team followed more than 29,000 adults from Lombardy aged 65 and older receiving uninterrupted treatment with statins,
